Lamivudine ViiV H-W-673

  • Email
  • Help
Name of the medicinal productLamivudine ViiV
Opinion holderViiV Healtcare UK Limited
Greenford Road
Greenford, Middlesex UB6 0NN
United Kingdom
Active substanceLamivudine
International non-proprietary name or common nameLamivudine
Pharmaco-therapeutic groupAntivirals for systemic use
ATC codeJ05AF05
Therapeutic indicationLamivudine is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (HIV) infected adults and children.
Orphan medicinal product designation dateNot applicable

This medicine was previously called: Lamivudine GSK

Back to top

Document(s) Language Status First published Last updated Effective Date
Lamivudine ViiV: Cessation of manufacture - Public statement (English only)   2015-12-21    
Lamivudine ViiV : Summary for the public (English only)   2009-12-02 2015-12-21  
Lamivudine ViiV : All presentations (English only)   2009-12-02 2015-12-21  
Lamivudine ViiV : Scientific discussion (English only)   2009-12-02 2015-12-21  
Lamivudine ViiV : Procedural steps taken before scientific opinion (English only)   2009-12-02 2015-12-21  
Lamivudine ViiV : Procedural steps taken and scientific information after opinion (English only)   2009-12-02 2015-12-21  

Product Information* 17/09/2015 Lamivudine ViiV H-W-673-WS-755

Back to top

Document(s) Language Status First published Last updated Effective Date
Lamivudine ViiV : Product information (English only)   2009-12-02 2015-12-21  

Related links

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.